Generalized Anxiety Disorder - Pipeline Insight, 2024

Generalized Anxiety Disorder - Pipeline Insight, 2024

DelveInsight’s, “Generalized Anxiety Disorder (GAD) – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Generalized Anxiety Disorder Understanding

Generalized Anxiety Disorder (GAD): Overview

Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. People with generalized anxiety disorder (GAD) display excessive anxiety or worry, most days for at least 6 months, about a number of things such as personal health, work, social interactions, and everyday routine life circumstances. The fear and anxiety can cause significant problems in areas of their life, such as social interactions, school, and work.

Symptoms

• Generalized anxiety disorder symptoms include:
• Feeling restless, wound-up, or on-edge
• Being easily fatigued
• Having difficulty concentrating; mind going blank
• Being irritable
• Having muscle tension
• Difficulty controlling feelings of worry
• Having sleep problems, such as difficulty falling or staying asleep, restlessness, or unsatisfying sleep

Generalized Anxiety Disorder is diagnosed with a mental health screening that a primary care provider can perform. They will ask questions about symptoms and how long the patient have had them. They can refer the patients to a mental health specialist, such as a psychologist or psychiatrist. If the primary care provider suspects that a medical condition or substance abuse problem is causing anxiety, they may perform more tests. These may include: blood tests, to check hormone levels that may indicate a thyroid disorder, urine tests, to check for substance abuse, gastric reflux tests, such as an X-ray of your digestive system or an endoscopy procedure to look at your esophagus, to check for GERD, X-rays and stress tests, to check for heart conditions. Treatment for Generalized Anxiety Disorder most often includes a combination of medication and cognitive behavioral therapy. Cognitive behavioral therapy: People being treated for anxiety disorders often take part in this type of therapy, in which they learn to recognize and change thought patterns and behaviors that lead to anxious feelings.

“Generalized Anxiety Disorder - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Anxiety Disorder pipeline landscape is provided which includes the disease overview and Generalized Anxiety Disorder treatment guidelines. The assessment part of the report embraces, in depth Generalized Anxiety Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.

Generalized Anxiety Disorder Emerging Drugs Chapters

This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Generalized Anxiety Disorder Emerging Drugs

• MM-120: Mind Medicine, Inc.

MM-120 is MindMed’s proprietary drug candidate, a pharmacologically optimized form of LSD being developed for GAD and other brain-based disorders. LSD was first synthesized in 1938 and its psychoactive properties were discovered in 1943. From 1949 to 1966, LSD was used by psychiatrists and researchers to gain insights into the world of brain health and to assist psychotherapy. LSD has been investigated for its applications in the treatment of anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression, among other conditions. In August 2022, Mind Medicine, Inc. announced first patient dosing in its Phase IIb dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD).

• ENX-102: Engrail therapeutics

ENX-102 is a GABAA α2,3,5 PAM that blocks α1; it is advancing into Phase II studies for the treatment of GAD. This profile is expected to facilitate sustained efficacy with chronic dosing and a favorable safety and tolerability profile that minimizes many of the risks and side effects associated with α1-mediated GABAergic transmission. The bioavailability and receptor occupancy of ENX-102 were engineered to deliver a best-in-class pharmacologic profile. ENX-102 has shown strong anxiolytic effects in a gold-standard preclinical model of GAD. In clinical studies, ENX-102 was well tolerated, with a pharmacokinetic profile supporting rapid onset of action and a predictable dose-related exposure with oral, once-daily dosing without the need for dose titration.

Further product details are provided in the report……..

Generalized Anxiety Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Generalized Anxiety Disorder

There are approx. 10+ key companies which are developing the therapies for Generalized Anxiety Disorder. The companies which have their Generalized Anxiety Disorder drug candidates in the mid to advanced stage, i.e. Phase II include, Mind Medicine, Inc.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Peptides
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Generalized Anxiety Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.

Generalized Anxiety Disorder Report Insights

• Generalized Anxiety Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Generalized Anxiety Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Generalized Anxiety Disorder drugs?
• How many Generalized Anxiety Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Anxiety Disorder?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Generalized Anxiety Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tilray
• Mind Medicine, Inc.
• PSY Therapeutics
• Pear Therapeutics
• Engrail Therapeutics
• Bionomics
• Sage Therapeutics
• Seed Health
• OWP Pharmaceuticals

Key Products

• Cannabidiol
• MM-120
• PSY-05
• Pear-011
• ENX-102
• BNC210
• Zuranolone
• Duloxetine Hydrochloride